Direct thrombin inhibitors in acute coronary syndromes: Present and future

Circulation

Volumn 105, Issue 8, 2002, Pages 1004-1011

  Weitz, Jeffrey I ^a   Buller, Harry R ^a  

^a HENDERSON RESEARCH CENTRE   (Canada)

Author keywords

Coronary disease; Inhibitors; Thrombin

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ANTICOAGULANT PROTEIN; ANTITHROMBIN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; EFEGATRAN; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRUDIN; HIRULOG; INOGATRAN; LOW MOLECULAR WEIGHT HEPARIN; PENTASACCHARIDE; STREPTOKINASE; TENECTEPLASE; THROMBIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; ENZYME BINDING; FIBRINOLYTIC THERAPY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THROMBOGENESIS; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ANTICOAGULANTS; CLINICAL TRIALS; CORONARY DISEASE; ENZYME INHIBITORS; FIBRIN; HUMANS; MACROMOLECULAR SUBSTANCES; THROMBIN; THROMBOSIS;

EID: 0037176941     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc0802.104331     Document Type: Review

References (53)

1. The pathogenesis of coronary artery disease and the acute coronary syndromes
2. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients
3. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndromes without ST elevation: A meta-analysis
4. Role of thrombin in arterial thrombosis: Implications for therapy
5. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy
6. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
7. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparinantithrombin but susceptible to inactivation by antithrombin- independent inhibitors
8. Binding of thrombin to subendothelial extracellular matrix: Protection and expression of functional properties
9. The influence of fibrinogen and fibrin on thrombin generation: Evidence for feedback activation of the clotting system by clot bound thrombin
10. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity
11. Heparin
12. Low molecular weight heparins
13. A player of many parts: The spotlight falls on thrombin's structure
14. Modulation of thrombin and heparin activities by fibrin
15. Molecular basis for the susceptibility of fibrin-bound thrombin inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin
16. Hirudins: From leeches to man
17. Effect of renal impairment on the pharmacokinetics and pharmacodynamics of desirudin
18. Design and characterization of Hirulogs: A novel class of bivalent peptide inhibitors of thrombin
19. Kinetic mechanism for the interaction of Hirulog with thrombin
20. Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans
21. The use of bivalirudin in patients with renal impairment
22. Novastan (brand of argatroban): A small-molecule, direct thrombin inhibitor
23. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
24. Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombin inhibitor, in patients with unstable angina
25. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction: ESCALAT Investigators
26. Heparin is more effective than inogatran, a low-molecular-weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease: Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group
27. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant Hirudin
28. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study
29. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial
30. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial
31. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study: A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte
32. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes
33. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
34. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the GUSTO-IIb Trial
35. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
36. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis
37. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction
38. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: Results of a randomised trial
39. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty
40. Antithrombotic therapy in patients undergoing percutaneous coronary intervention
41. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina
42. Bivalirudin versus heparin during coronary angioplasty for unstable or post-infarction angina: The final report of the Bivalirudin Angioplasty Study
43. Defining the optimal activated clotting time during percutaneous coronary intervention: Aggregate results from 6 randomized, controlled trials
44. Argatroban and alteplase in patients with acute myocardial infarction: The ARGAMI Study
45. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
46. Challenges in the conduct and interpretation of phase II (pilot) randomized trials
47. Clinical outcomes of bivalirudin for ischemic heart disease
48. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction
49. The direct thrombin inhibitor melagatran and its oral prodrug H376/95: Intestinal absorption properties. Biochemical and pharmacodynamic effects
50. New anticoagulant drugs
51. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hipfracture surgery
52. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery
53. Dose-response study of the factor VIIa/tissue factor inhibitor nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement